How Covid-19 Is Changing the Future of Vaccines

In his December 24, 2020, video report, "The Future of Vaccines," investigative journalist James Corbett reviews how the novel COVID-19 vaccine is paving the way for nonconsensual medical experimentation on the general public.

January 12, 2021 | Source: Mercola.com | by Dr. Joseph Mercola

In his December 24, 2020, video report,1,2 “The Future of Vaccines,” investigative journalist James Corbett reviews how the novel COVID-19 vaccine is paving the way for nonconsensual medical experimentation on the general public.

As noted by Corbett, if the international medical establishment get their way, nothing will get back to “normal” until world health officials have definitively determined there is an effective COVID vaccine in place.

Even then, however, things may not go back to the normal we’re accustomed to or expect. Since the beginning of the pandemic, world leaders have warned that social distancingmask wearingtravel restrictions and other measures will become part of our “new normal.”3

Be that as it may, the refrain we keep hearing from the likes of Bill Gates, Dr. Anthony Fauci and a long list of other world leaders is that any sense of normalcy will remain elusive until or unless the entire global population gets vaccinated against SARS-CoV-2

Brave New World of Vaccines 

“The public is being prepared for an unprecedented global vaccination campaign,” Corbett says. However, one major problem with this is that the current COVID-19 vaccines are still in the experimental stage. While they’ve been granted emergency use authorization, they still haven’t completed Stage 3 clinical trials. Data for some end points won’t even be collected until 24 months after injection.

Another problem is that the COVID vaccines’ adverse side effects are still relatively unknown due to the “fanatical” warp speed at which they were developed. 

Even if there is only one serious event per 1,000 people, cumulatively that would equate to 100,000 people being harmed by the vaccine for every 100 million vaccinated — a steep price for an infection that has an overall noninstitutionalized infection fatality rate of just 0.26%.4 Among those under the age of 40, the infection fatality rate is a mere 0.01%, which is lower than that for seasonal influenza.5

A third issue that Corbett homes in on in his report is the fact that the COVID-19 vaccines are “unlike any vaccines that have ever been used on the human population before,” and “as radically different as these vaccines appear, they represent only the very beginning of a complete transformation of vaccine technology that is currently taking place in research labs across the planet.”6

Are COVID-19 Vaccines Really as Effective as Advertised?

On an important side note, while Pfizer’s and Moderna’s vaccines have reported very high success rates, their “success” is only measured by their ability to lessen moderate to severe COVID-19 symptoms such as cough and headache. Presumably, this would lower the risk of hospitalization and death for vaccinated individuals.

However, as explained in “How COVID-19 Vaccine Trials Are Rigged,” the vaccines were not evaluated for their ability to actually prevent infection and transmission of the virus. So, since the vaccine cannot reduce infection, hospitalizations or deaths, it cannot create vaccine-acquired herd immunity and end the pandemic, even though this has been the vaccine’s primary selling point. Furthermore, as noted by Corbett:7

“The studies are touted as involving tens of thousands of people, but in Pfizer’s trial, only 170 of them were reported as being ‘diagnosed with COVID-19’ during the trial. Of those, 162 were in the placebo group and eight were in the vaccine group. 

From this, it is inferred that the vaccine prevented 154/162 people from developing the disease, or ‘95%.’ But as even the British Medical Journal points out,8 ‘a relative risk reduction is being reported, not absolute risk reduction, which appears to be less than 1%.'”